About us

Company profile

Company name Curadim Pharma Co., Ltd.
Head office Otemachi Financial City Grand Cube 3F, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, JAPAN
Tel: +81-3-4243-8654
Establishment June 29, 2016
Scope of business Research and development of pharmaceutical products
Representative Tetsu Uchigasaki, Chief Executive Officer

Corporate history

June 2016 Curadim Pharma was established with the mission of “Discover unutilized innovative drug seeds in Japan” and “Develop novel medicines for refractory diseases.”
July 2016 The head office was moved to Chiyoda-ku, Tokyo.
July 2016 A S1P receptor modulator “CP1050” was in-licensed from Meiji Seika Pharma Co., Ltd.
August 2016 1,330 million yen (approximately 12 million US dollars) was raised through a third-party allocation of new shares to the Innovation Network Corporation of Japan; SMBC Venture Capital Co., Ltd.; Nippon Venture Capital Co., Ltd.; Nissay Capital Co., Ltd.; and Mitsubishi UFJ Capital Co., Ltd.
February 2018 Phase 1 clinical trial of “CP1050” was started in the UK.
March 2018 A LPA1 selective antagonist “CP2090” was in-licensed from Ube Industries, Ltd.
June 2018 1,176 million yen (approximately 11 million US dollars) was raised through a third-party allocation of new shares to the Innovation Network Corporation of Japan; SMBC Venture Capital Co., Ltd.; DBJ Capital Co., Ltd.; and Yamaguchi Capital Co., Ltd.

Management team

Chief Executive Officer Tetsu Uchigasaki
Tetsu Uchigasaki has >30 years diverse experience in research and development in Daiichi Sankyo Co., Ltd., including project management in Japan and abroad; overseas clinical development (in the US); regulatory affairs in Asia, the US, and Europe; and out-licensing business. He contributed to the development and acquisition of market approval of leading products, such as antibacterial agents, irinotecan, Olmetec, and edoxaban.
He joined Curadim Pharma in June 2016, when it was established, as Chief Executive Officer.
Chief Development Officer Tadaki Sugawara, Ph.D., D.J.S.T
Dr. Tadaki Sugawara has 20 years experience in non-clinical safety research in Daiichi Sankyo Co., Ltd. During his career, he promoted drug development research in extensive therapeutic areas, including the discovery of antibacterial, anticoagulant, and contrast agents. Subsequently, he served as a non-clinical liaison and regulatory writer for 3 years at a US subsidiary. After returning to Japan, he was engaged in regulatory writing of non-clinical studies in Japan and overseas using his experience of non-clinical research and regulatory affairs and contributed to marketing applications of anticoagulant agents submitted in Japan, the US, and Europe.
He joined Curadim Pharma in June 2016, when it was established, as Chief Development Officer. He is mainly responsible for non-clinical safety studies and regulatory affairs.
Chief Scientific Officer Tomohisa Ninomiya
Tomohisa Ninomiya is an inventor of our 1st pipeline “CP1050.” He has 19 years experience in drug discovery research, primarily in immunology in Meiji Seika Pharma Co., Ltd. He held a lot of leadership positions in research projects on multiple sclerosis, ulcerative colitis, and other disease. He was also engaged in business development targeted at immune-mediated and inflammatory disease.
He had been temporarily transferred to Curadim Pharma in August 2018 as Chief Scientific Officer. He officially joined Curadim Pharma in January 2018 as a director. He is mainly responsible for pharmacological tests; chemistry, manufacturing, and controls; and business development (in-licensing).
Chief Medical Officer Tomohiko Harada, M.D., Ph.D.
Dr. Tomohiko Harada has earned M.D. and Ph.D. degrees at Yamaguchi University School of Medicine. He has 7 years experience as a gastroenterologist in Japan. In 2003, he moved to the UK and continued his oncology research project at Imperial College London for 5 years. After gaining an industry experience in the UK Phase 1 unit as a Clinical Project Leader, he joined Mitsubishi Tanabe Pharma Europe Ltd., where he spent over 7 years as a Global Medical Lead. He has an extensive knowledge, expertise, and network for global clinical development in immune-mediated and inflammatory diseases, such as multiple sclerosis and inflammatory bowel disease. He has published numerous papers in peer-reviewed medical journals, including Lancet Neurology and Cancer Research.
He joined Curadim Pharma in July 2017 as a Chief Medical Officer and has an overall responsibility of clinical development. He is based in London, the UK.
Chief Financial Officer Hiroshi Yokoyama, CPA
Hiroshi Yokoyama has 16 years experience in financial audit at Ernst & Young ShinNihon LLC. He was in charge of auditing for various industries, such as major financial institutions, manufacturing companies, investment limited partnership, and contract research organisation. He had been temporarily transferred to a biotech company for 2 years during his career with an auditing firm. He was responsible for general administration and was involved in actively management as a Chief Financial Officer and achieved funds.
He joined Curadim Pharma in July 2016 as Chief Financial Officer and is responsible for the entire administration, including financing, accounting, human resources, and legal affairs.

Access map

Global Business Hub Tokyo, Otemachi Financial City Grand Cube 3F, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, JAPAN
Tel: +81-3-4243-8654
A 10 minute walk from “Tokyo” Station (JR line)
A 3-8 minute walk from “Otemachi” Stations (Subway lines)
Access from the underground mall is depicted below.
launch Global Business Hub Tokyo